Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants
出版年份 2020 全文链接
标题
Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants
作者
关键词
NTRK, Kinase inhibitor, TRK mutant, Drug resistance
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 207, Issue -, Pages 112744
出版商
Elsevier BV
发表日期
2020-08-31
DOI
10.1016/j.ejmech.2020.112744
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of (E)-N1-(3-Fluorophenyl)-N3-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs)
- (2019) Xuesong Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors
- (2019) Yun Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effects of rigidity on the selectivity of protein kinase inhibitors
- (2018) Amir Assadieskandar et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
- (2018) Wei Yan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors
- (2018) Jason G. Kettle et al. JOURNAL OF MEDICINAL CHEMISTRY
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia
- (2018) Xuesong Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Targeting TRK family proteins in cancer
- (2017) Yekaterina B. Khotskaya et al. PHARMACOLOGY & THERAPEUTICS
- A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
- (2017) Alexander Drilon et al. Cancer Discovery
- Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I “Gatekeeper” Mutant of cKIT Kinase
- (2016) Binhua Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
- (2016) Maria Menichincheri et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- Classification of scaffold-hopping approaches
- (2011) Hongmao Sun et al. DRUG DISCOVERY TODAY
- Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
- (2009) Carie S. Facemire et al. HYPERTENSION
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now